Journal of Alzheimers Disease & Parkinsonism
Open Access

Conference Proceeding

Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases

Diane Stephenson^1*, Martha Brumfield¹, Klaus Romero¹, Janet Woodcock², Issam Zineh², Eric M Reiman³, Caroline Tanner⁴, Richard Mohs⁵, Walter Koroshetz⁶, Timothy Nicholas⁷, Lisa J Bain⁸, Derek Hill⁹, Les Shaw¹⁰, Johan Luthman¹¹, Michael Ropacki¹², Richard Meibach¹³, Peter Loupos¹⁴, Ken Marek¹⁵, James Hendrix¹⁶, Eric Karran¹⁷, George Vradenburg¹⁸, Keiju Motohashi¹⁹, Jesse M Cedarbaum²⁰ and Mark Forrest Gordon²¹

¹Critical Path Institute, CAMD, Tucson, AZ, USA

²Office of Clinical Pharmacology, FDA, New Hampshire Ave, Silver Spring, USA

³Banner Alzheimer’s Institute, AZ, USA

⁴University of California – San Francisco, San Francisco, CA, USA

⁵Lilly Corporate Center, Indianapolis, IN, USA

⁶NINDS,Bethesda, MD, USA

⁷Pfizer, Groton, CT, USA

⁸Independent Scientific & Medical Writer, Elverson, PA, USA

⁹Ixico, London, UK

¹⁰Hospital of the University of Pennsylvania, Philadelphia, PA, USA

¹¹Eisai,Woodcliff Lake, , USA

¹²Janssen R&D, South San Francisco, CA, USA

¹³Novartis,East Hanover, NJ, USA

¹⁴Sanofi, Bridgewater, NJ, USA

¹⁵Institute for Neurodegenerative Disorders, New Haven, CT, USA

¹⁶Alzheimer’s Association, Chicago, IL, USA

¹⁷Alzheimer’s Research UK, Cambridge,UK

¹⁸USAgainstAD, Washington, DC, USA

¹⁹Office of New Drug II,The University of Tokyo Hospital, Tokyo, Japan

²⁰Neurology Clinical Development, Cambridge, MA

²¹Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA

Corresponding Author:

Diane Stephenson, PhD
Critical Path Institute
1730 E. River Road, Tucson, AZ 85718
Tel: 520-382-1405
Fax: 520-547-3456
E-mail: dstephenson@c-path.org

Received date: February 25, 2015; Accepted date: March 14, 2015; Published date: March 31, 2015

Citation: Stephenson D, Brumfield M, Romero K, Woodcock J, Zineh I, et al. (2015) Alzheimer’s and Parkinson’s Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases. J Alzheimers Dis Parkinsonism 5:183. doi:10.4172/2161-0460.1000183

Copyright: © 2015 Stephenson D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint efforts, pooling resources and expertise,are required for theadvancement of methods and tools that are critically needed to support drug development studies. Critical Path Institute’s Coalition against Major Diseases was formed in 2008, at a time prior to the era of public private partnerships, with the mission of streamlining and de-risking drug development for AD and PD. Since its origin, the consortium has achieved several milestones including development of consensus data standards for AD and PD, a unified clinical trial database comprised of placebo data from AD therapeutic trials and regulatory endorsement of drug development tools. In addition, the consortium is progressing strongly on other initiatives, with ongoing regulatory interactions. The coalition held its annual conference at the U.S. Food and Drug Administration, where diverse stakeholders including industry, academic experts, government agency representatives, patient advocacy organizations and regulators gathered together to share their accomplishments and focus on the needs of the future. The current landscape was emphasized with focus on the need to expand the precompetitive space and enhance data sharing globally.

Keywords